Basilea receives request to place repayment of CHF 48 million from capital contribution reserve on the agenda of the ordinary general meeting of shareholders

2013-02-22 23:52:39 -
Basilea Pharmaceutica AG /
Basilea receives request to place repayment of CHF 48 million from capital 
contribution reserve on the agenda of the ordinary general meeting of 
shareholders 
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Basel, Switzerland, February 22, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
has received a request from one of its shareholders, HBM Healthcare Investments
(Cayman) Ltd., which holds more than 20% of Basilea's shares, to place the
repayment of CHF 5.00 per registered share from the company's capital
contribution reserve on the agenda of Basilea's upcoming ordinary general
meeting of shareholders, for a total of approximately CHF 48 million.

Basilea's board of directors will carefully evaluate the request.

Basilea's ordinary general meeting of shareholders 
  
    
      
        

	    
  
  is scheduled for April
9, 2013. The deadline for registration in the share register to vote at the
ordinary general meeting of shareholders is March 28, 2013.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the company focuses on innovative pharmaceutical products in
the therapeutic areas of bacterial infections, fungal infections and oncology,
targeting the medical challenge of rising resistance and non-response to current
treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.

For further information, please contact:

+-----------------------------+--------------------------------+
| Media Relations             | Investor Relations             |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, Ph.D.   | Barbara Zink, Ph.D., MBA       |
| Head Public Relations &     | Head Corporate Development     |
| Corporate Communications    |                                |
| +41 61 606 1102             | +41 61 606 1233                |
| media_relations@basilea.com | investor_relations@basilea.com |
+-----------------------------+--------------------------------+

This press release can be downloaded from www.basilea.com.


Press release (PDF): 
 hugin.info/134390/R/1680620/549123.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1680620]